Induction chemotherapy followed by definitive chemoradiation: A new nonsurgical strategy for treating esophageal cancer?

摘要

Neoadjuvant chemotherapy consisting of cisplatin and 5-fluorouracil, followed by esophagectomy with three-field lymphadenectomy is the current standard therapy for clinical stage Will thoracic esophageal squamous cell carcinoma (ESCC) in Japan according to the results of JCOG9907. However, definitive chemoradiation (CRT) without planned esophagectomy is also an attractive treatment option currently available for locally advanced ESCC. Definitive CRT may allow esophageal preservation as a nonsurgical approach, although it can result in long-term survival rates of 30% to 45% [1,21.